Business Wire

SVANTE/CLIMEWORKS

30.1.2024 16:01:32 CET | Business Wire | Press release

Share
Climeworks and Svante Collaborate in Development and Supply for Direct Air Capture

Climeworks has signed a collaboration and supply agreement with Svante Technologies Inc. (Svante), a leading carbon capture and removal solutions provider. The companies agreed to jointly plan the supply of Svante’s contactor blocks for three major Climeworks projects, intending to lead to a commercial-scale supply agreement, whereby Climeworks would purchase Svante’s contactor blocks for its planned megaton direct air capturing hubs in the US.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130940532/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Claude Letourneau, President & CEO, Svante (Photo: Business Wire)

The US Department of Energy selected Climeworks to develop three of these hubs, in Louisiana, California, and North Dakota, making the company eligible for a total of more than USD 600 million in government funding.

Combined forces for global carbon removal

The collaboration allows both partners to agree on intermediate goals, and to jointly proceed to the next phase of development. “Delivering large-scale direct air capture required us to approach this collaboration with flexibility on the development of project specifications while retaining rigorous accountability for the success of the overall project,” says Claude Letourneau, President and CEO of Svante. “We’ve been closely collaborating with Climeworks over the past three years, and because of that proximity, we felt comfortable entering into this kind of arrangement. The combination of our advanced technologies represents a significant step forward in the nascent direct air capture industry, playing a critical role in meeting the world’s net-zero ambitions.”

Svante is in the final stages of building its commercial filter manufacturing facility, The Centre of Excellence for Carbon Capture and Removal, in Vancouver, BC, Canada. The Centre is equipped to supply both the industrial point source post-combustion carbon capture market and the direct air capture market. Svante has anticipated and prepared for the event where the agreement with Climeworks takes up a significant portion of the Centre’s capacity and has secured additional coating capacity with its partner, 3M.

Best-in-class technology for Climeworks’ large-scale direct air capture projects

With the extended collaboration, Climeworks secures best-in-class technology supporting its scale-up journey. A crucial part of the direct air capture process involves filter material trapping CO2 from the ambient air, and Svante’s filter technology will further enhance the performance of the carbon dioxide capturing process.

“We are focusing on the massive growth of our carbon removal technology to create climate impact,” says Jan Wurzbacher, Co-Founder and Co-CEO of Climeworks. “Svante is one of the key players in the ecosystem to support us in our journey to scale to a gigaton capacity.”

About Svante

Svante is a purpose-driven, leading carbon capture and removal solutions provider. The Vancouver, Canada-based company manufactures nanoengineered filters and modular rotary contactor machines that capture and remove CO2 from industrial emissions and the air in an environmentally responsible manner. Svante is on the 2024 Global Cleantech 100, the XPRIZE Foundation’s XB100 – World’s Top 100 Deep Tech Companies and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies. For more information, visit www.svanteinc.com and follow Svante on LinkedIn at www.linkedin.com/company/svantesolutions.

About Climeworks

Climeworks is the global leader in carbon dioxide removal (CDR) as a service via direct air capture (DAC) technology, empowering companies to advance their net zero roadmaps and fight climate change. Founded by engineers Christoph Gebald and Jan Wurzbacher in 2009, Climeworks is on a journey to climate impact at scale with integrity at its core and a focus on high-quality, permanent carbon removals.

Climeworks is spearheading the DAC industry globally, with the world’s only commercial DAC facility combined with storage installation in operation, modular CO2 collectors designed for scalability, and facilities running on renewable energy. Their growing customer base counts over 160 companies, including multinationals such as Microsoft, BCG, UBS, and Swiss Re.

At Orca, Climeworks’ DAC facility in Iceland, the CO2 is permanently removed from the air by capturing and geologically storing it for thousands of years with Climeworks’ underground mineralization partner Carbfix. The CDR services delivered from Orca are verified by independent 3rd party DNV.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130940532/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye